Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine +

KITS Eyecare Reports Record First Quarter 2026 Results

KITS Eyecare Beats Margins on Glasses Surge Despite Revenue Miss

Executive Summary
  • KITS Eyecare reported Q1 2026 revenue of $57.5 million, a 23.3% increase year-over-year.
  • Adjusted EBITDA reached $4.1 million with a 7.2% margin, exceeding the previous guidance range of 3.0% to 5.0%.
  • Net income was $2.0 million ($0.06 per share), up from $1.6 million in Q1 2025.
  • The glasses segment drove significant growth with revenue up 60.5% YoY to $10.8 million and units delivered up 50%.
  • Premium lens upgrades increased 75.5% YoY, accounting for 41.8% of glasses revenue.
  • Liquidity remains strong with cash at $19.0 million; the company fully repaid its BMO asset-based lending facility balance on January 2, 2026, leaving $15 million available and undrawn.
  • Q2 2026 guidance was issued for revenue of $57.0 million to $59.0 million and Adjusted EBITDA margin of 3.0% to 5.0%.
Material Impact
  • The earnings release confirms the company's trajectory established in February 2026 guidance, validating the growth thesis without a major deviation.
  • Revenue of $57.5 million slightly missed the upper end of the previous guidance range ($58M-$60M) but remained within the lower bound expectations.
  • The Adjusted EBITDA margin beat (7.2% vs 3-5% guidance) is a positive surprise indicating improved operational leverage and cost control.
  • Debt-free status with an undrawn $15 million credit facility reduces financial risk and provides flexibility for future marketing or expansion without dilution.
  • The stock has corrected significantly from January highs ($21.93) to current levels ($14.29); this news acts as a fundamental floor but does not immediately reverse the technical downtrend seen in Q1 2026.
  • No new strategic investors or M&A activity was announced, limiting the potential for an immediate re-rating event compared to previous quarters.
KITS · Price
Company Overview
  • KITS Eyecare operates a vertically integrated, digital-first vision care platform focusing on prescription eyewear and contact lenses.
  • Flagship product includes the Pangolin AI glasses (Gen 3 currently active), with Gen 4 planned for 2026 featuring camera, video, voice, and full AI integration.
  • The company has expanded its physical footprint with a Vancouver flagship store and is opening a second Toronto location in Q1 2026.
  • Customer metrics show strong retention with repeat orders accounting for over 63% of total revenue in Q1 2026.
  • Two-year active customer base reached 1,108,000, up 17.1% year-over-year.
Read the original news release →

More from KITS EYECARE LTD.